866-997-4948(US-Canada Toll Free)

Avastin (Head and Neck Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Head and Neck Cancer

No. of Pages : 30 Pages


Summary

GlobalDatas pharmaceuticals report, Avastin (Head and Neck Cancer) Analysis and Forecasts to 2020 provides Avastin sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Head and Neck Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review ofAvastin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Avastin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2015-2020 for Avastin in the Japan

Reasons to buy

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 8
2.4 GlobalData Analysis and Forecasts Report Guidance 9


3 Head and Neck Cancer Disease: Market Characterization 10
3.1 Head and Neck Cancer Disease Market 10
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 10
3.3 Drivers for the Head and Neck Cancer Disease Market 11
3.3.1 High Incidence 11
3.3.2 Low Initial Diagnosis Rate 12
3.3.3 Emergence of Targeted Therapies and Vaccines 12


4 TumorNodeMetastases (TNM) Classification of Head and Neck Cancer 13


5 Avastin (Bevacizumab) 21
5.1 Introduction 21
5.2 Mechanism of Action 21
5.3 Clinical Studies 21
5.4 Approval History of Avastin 21
5.5 Avastin Sales Drivers 22
5.5.1 Head and Neck Cancer Market 22
5.5.2 Targeted Therapy 22
5.5.3 High Efficacy 22
5.5.4 Wide Acceptance 22
5.6 Drug Risk Benefit Score 22
5.6.1 Efficacy 23
5.6.2 Safety 23
5.6.3 Compliance 23
5.6.4 Dosing Convenience 23
5.7 Intensity of Competition 23
5.8 Sales forecast 23
5.8.1 Target patient Pool of Avastin 24
5.8.2 Dosing 24
5.8.3 Market Penetration 24
5.8.4 Annual Cost of Therapy 24
5.8.5 Sales Projections of Avastin 25


6 Head and Neck Cancer Market: Appendix 26
6.1 Market Definitions 26
6.2 Abbreviations 26
6.3 Research Methodology 26
6.3.1 Coverage 27
6.3.2 Secondary Research 27
6.3.3 Forecasting 27
6.3.4 Number of Patients Approved to take the Drug 28
6.3.5 Net Penetration of Drug 28
6.3.6 Net Annual Dosing 29
6.3.7 Annual Cost of Therapy 29
6.3.8 Primary Research 29
6.3.9 Expert Panels 29
6.4 Contact Us 30
6.5 Disclaimer 30
6.6 Sources 30

List of Table


Table 1:Head and Neck Cancer Incidences and Mortality, 2008-2030 4
Table 2: Head and Neck Cancer, Market Forecasts ($bn), Global, 20092020 11
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 13
Table 4: TNM Classification of the Nasopharyngeal Cancer 18
Table 5: Approval History of Avastin 21
Table 6: Drug Risk Benefit Score of Avastin 23
Table 7: Avastin Sales Forecast ($m), the US, 20152020 25

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers, Based on Incidence Global, 2008 5
Figure 2: Percentage Distribution of Top 20 Cancers, Based on Mortality Global, 2008 6
Figure 3: Difference Between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 7
Figure 4: Percentage Distribution of Various Cancer Types in Head and Neck Considering US, EU-5 and Japan Incidence, 2008 7
Figure 5: Percentage Distribution of Various Cancer Types in Head and Neck Considering Global Incidence, 2008 8
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 9
Figure 7: Head and Neck Cancer, Market Forecasts ($bn), Global, 20092020 10
Figure 8: Oncology Incidence (in billion), Global, 2008-2030 11
Figure 9: Head and Neck Cancer Incidence (in billion), Global, 2008-2030 12
Figure 10: Broad Classification of Head and Neck Cancer 13
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 14
Figure 12: Detailed TNM Classification of Laryngeal Cancer 15
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 16
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 17
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 19
Figure 16: Classification of Head and Neck Cancer 20
Figure 17: Drug Model Diagram of Avastin 24
Figure 18: Avastin Sales Forecast ($m), the US, 20152020 25
Figure 19: GlobalData Methodology 26
Figure 20: Drug Model Diagram 28
Figure 21: Patients Approved for the Drug 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *